<DOC>
	<DOCNO>NCT01349673</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability cyclically dose rectal budesonide foam subject active ulcerative proctitis ( UP ) ulcerative proctosigmoiditis ( UPS ) .</brief_summary>
	<brief_title>The Safety Tolerability Budesonide Foam Subjects With Active Ulcerative Proctitis Proctosigmoiditis</brief_title>
	<detailed_description>This Phase 3 , multicenter , open label study subject participate previously Salix-sponsored budesonide rectal foam study treatment ulcerative proctitis proctosigmoiditis . Approximately 300 subject enrol study receive budesonide foam cyclically 6 week ( BID 2 week QD 4 week ) time ulcerative proctitis proctosigmoiditis flare . The study continue regulatory approval budesonide foam occur , sponsor decides terminate study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Proctitis</mesh_term>
	<mesh_term>Proctocolitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<criteria>Male nonpregnant , non breastfeeding female â‰¥ 18 year old . Subject previously diagnose active mild moderate UP/UPS currently experience symptom active UP/UPS disease complete participation Salix 's BUCF3001 BUCF3002 study . Willingness undergo sigmoidoscopy . Active systemic , ocular cutaneous infection ( e.g. , parasitic , fungal , amoebic , viral bacterial disease ) . History sclerosing cholangitis , cirrhosis , hepatic impairment , include chronic hepatitis etiology . Subject take systemic , inhale , oral , topical rectal corticosteroid ( budesonide rectal foam ) within 7 day start treatment cycle . Subject take ketoconazole potent CYP3A4 inhibitor within 7 day start treatment cycle . Subjects take diuretic cardiac glycoside . Unstable significant cardiovascular , hepatic , renal , endocrine , neurologic pulmonary disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Open-label</keyword>
	<keyword>Proctitis</keyword>
	<keyword>Proctosigmoiditis</keyword>
	<keyword>Ulcerative</keyword>
	<keyword>Salix</keyword>
	<keyword>Budesonide foam</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Rectal</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Colitis</keyword>
	<keyword>UC</keyword>
	<keyword>UP</keyword>
	<keyword>UPS</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Proctocolitis</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Colitis , Ulcerative</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Sigmoid Diseases</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Bronchodilator Agents</keyword>
	<keyword>Autonomic Agents</keyword>
	<keyword>Peripheral Nervous System Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-Asthmatic Agents</keyword>
	<keyword>Respiratory System Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones , Hormone Substitutes Hormone Antagonists</keyword>
	<keyword>Anti-inflammatory Agents</keyword>
</DOC>